SCHEMBL838436

SCHEMBL838436

N#Cc1cnn(-c2ncc(Cl)cc2C(F)(F)F)c1N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.40
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
XDH P47989 2/20 0.38
RXFP1 Q9HBX9 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
AR P10275 3/20 0.35
MALT1 Q9UDY8 1/20 0.33
GLA P06280 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10913942 0.82 KMT2A (0.46) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL6475236 0.80 KDM4E (0.49) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL6949643 0.79 KMT2A (0.43) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL7779112 0.78 KMT2A (0.45) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL10616527 0.77 KMT2A (0.44) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL8531966 0.76 KMT2A (0.39) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL8026458 0.75 GABRA2 (0.54) KMT2AKDM4EMEN1ALDH1A1LMNA
SCHEMBL8043436 0.74 KMT2A (0.56) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL7786140 0.74 KMT2A (0.39) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL10848533 0.74 GABRA2 (0.53) KMT2AKDM4EMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
CN-102171213-A Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity ASTRAZENECA AB 2011-08-31 CN disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 KMT2A 4136/4885KDM4E 3541/4885MEN1 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.